Dawson-Hughes Bess, Chen Peiqi, Krege John H
Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, 711 Washington Street, Boston, Massachusetts 02111-1524, USA.
J Clin Endocrinol Metab. 2007 Dec;92(12):4630-6. doi: 10.1210/jc.2007-0239. Epub 2007 Oct 2.
Serum 25-hydroxyvitamin D (25OHD) concentrations greater than 30 ng/ml have been recommended for lowering fracture risk.
Our objective was to determine whether 25OHD sufficiency is a prerequisite for effective response to teriparatide (TPTD).
Data were from 1620 osteoporotic postmenopausal women in the Fracture Prevention Trial. The response to TPTD was assessed in women subgrouped by having 25OHD insufficiency (>10 but <or=30 ng/ml) or 25OHD sufficiency (>30 but <or=183 ng/ml) at the baseline (randomization) visit. An abnormal intact PTH was exclusionary.
At baseline, after at least 1 month of supplementation with calcium (1000 mg) and vitamin D (400-1200 IU) daily, women were randomized to placebo or 20 or 40 microg TPTD by daily sc injection for a median of 19 months. Observation was for a median of 21 months.
Main outcome measures included vertebral and nonvertebral fractures, change in bone mineral density at the lumbar spine and femoral neck, change in bone formation marker amino-terminal extension peptide of procollagen type 1, and the proportion of women with serum calcium at least 2.76 mmol/liter 4-6 h after dosing.
TPTD reduced vertebral and nonvertebral fracture risk, increased lumbar spine and femoral neck bone mineral density, and increased amino-terminal extension peptide of procollagen type 1 relative to placebo in the two 25OHD subgroups. There were no significant differences in these endpoints between the subgroups (each treatment by subgroup interaction, P > 0.10). However, it should be noted that because of the limited number of fractures, this study does not exclude the possibility of differences in fracture outcome between the subgroups.
In postmenopausal women with osteoporosis and normal intact PTH, the responses to TPTD did not differ significantly in women with baseline 25OHD insufficiency or sufficiency.
血清25-羟维生素D(25OHD)浓度大于30 ng/ml被推荐用于降低骨折风险。
我们的目的是确定25OHD充足是否是有效应答特立帕肽(TPTD)的先决条件。
数据来自骨折预防试验中的1620名绝经后骨质疏松女性。在基线(随机分组)访视时,根据25OHD不足(>10但≤30 ng/ml)或25OHD充足(>30但≤183 ng/ml)对女性进行亚组划分,评估她们对TPTD的应答情况。排除甲状旁腺激素异常者。
在基线时,在每天补充钙(1000 mg)和维生素D(400 - 1200 IU)至少1个月后,女性被随机分为安慰剂组或每日皮下注射20或40μg TPTD组,中位治疗时间为19个月。中位观察时间为21个月。
主要结局指标包括椎体和非椎体骨折、腰椎和股骨颈骨密度变化、骨形成标志物1型前胶原氨基端前肽变化,以及给药后4 - 6小时血清钙至少为2.76 mmol/L的女性比例。
相对于安慰剂,在两个25OHD亚组中,TPTD均降低了椎体和非椎体骨折风险,增加了腰椎和股骨颈骨密度,并增加了1型前胶原氨基端前肽。亚组间这些终点指标无显著差异(各治疗与亚组交互作用,P>0.10)。然而,应注意的是,由于骨折数量有限,本研究并未排除亚组间骨折结局存在差异的可能性。
在绝经后骨质疏松且甲状旁腺激素正常的女性中,基线25OHD不足或充足的女性对TPTD的应答无显著差异。